Engineers Gate Manager LP Raises Stock Holdings in Health Catalyst, Inc. (NASDAQ:HCAT)

Engineers Gate Manager LP increased its stake in shares of Health Catalyst, Inc. (NASDAQ:HCATGet Rating) by 128.9% during the 1st quarter, HoldingsChannel.com reports. The firm owned 117,471 shares of the company’s stock after purchasing an additional 66,141 shares during the quarter. Engineers Gate Manager LP’s holdings in Health Catalyst were worth $3,070,000 at the end of the most recent quarter.

Other large investors have also recently modified their holdings of the company. UMB Bank N A MO bought a new position in shares of Health Catalyst during the 4th quarter valued at approximately $30,000. Fairfield Bush & CO. bought a new position in shares of Health Catalyst during the 1st quarter valued at approximately $25,000. Manchester Capital Management LLC increased its position in shares of Health Catalyst by 667.5% during the 1st quarter. Manchester Capital Management LLC now owns 1,159 shares of the company’s stock valued at $30,000 after purchasing an additional 1,008 shares during the last quarter. Advisor Group Holdings Inc. increased its position in shares of Health Catalyst by 94.9% during the 4th quarter. Advisor Group Holdings Inc. now owns 2,857 shares of the company’s stock valued at $113,000 after purchasing an additional 1,391 shares during the last quarter. Finally, Hardy Reed LLC bought a new position in shares of Health Catalyst during the 1st quarter valued at approximately $80,000. Institutional investors own 96.58% of the company’s stock.

Health Catalyst Trading Up 3.6 %

HCAT opened at $11.54 on Monday. Health Catalyst, Inc. has a 12-month low of $10.72 and a 12-month high of $57.19. The business’s fifty day simple moving average is $14.10 and its 200-day simple moving average is $17.48. The company has a market capitalization of $631.50 million, a price-to-earnings ratio of -3.95 and a beta of 1.23.

Health Catalyst (NASDAQ:HCATGet Rating) last posted its quarterly earnings results on Thursday, August 4th. The company reported ($0.36) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.09. Health Catalyst had a negative return on equity of 18.31% and a negative net margin of 54.64%. The business had revenue of $70.63 million for the quarter, compared to the consensus estimate of $69.78 million. On average, equities research analysts predict that Health Catalyst, Inc. will post -1.82 EPS for the current year.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on the company. BTIG Research cut their target price on Health Catalyst from $35.00 to $25.00 in a research report on Wednesday, July 27th. The Goldman Sachs Group cut their price objective on Health Catalyst from $29.00 to $18.00 and set a “buy” rating on the stock in a research report on Wednesday, August 10th. JPMorgan Chase & Co. downgraded Health Catalyst from an “overweight” rating to a “neutral” rating and cut their price objective for the company from $20.00 to $16.00 in a research report on Friday, August 5th. Finally, Stifel Nicolaus downgraded Health Catalyst from a “buy” rating to a “hold” rating and cut their price objective for the company from $27.00 to $16.00 in a research report on Friday, August 5th. Two research analysts have rated the stock with a hold rating, nine have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, Health Catalyst has a consensus rating of “Moderate Buy” and a consensus target price of $26.69.

Insider Transactions at Health Catalyst

In other news, Director Duncan Gallagher purchased 8,400 shares of the company’s stock in a transaction dated Thursday, August 18th. The shares were acquired at an average price of $11.69 per share, with a total value of $98,196.00. Following the transaction, the director now owns 28,805 shares of the company’s stock, valued at $336,730.45. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. In the last 90 days, insiders have sold 1,964 shares of company stock valued at $27,090. 1.50% of the stock is currently owned by corporate insiders.

Health Catalyst Profile

(Get Rating)

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations. Its offerings include data and analytics platform, a commercial-grade data and analytics platform for the healthcare sector; AI and data science, providing integration of AI into existing business intelligence tools, increasing analytics accuracy; population health management identifies improvement across the care continuum as well as actionable guidance for success and automated workflows; financial transformation providing costing and labor productivity insights and revenue capture; quality and safety improvement using clinical quality and patient safety data, analytics, and expert services; and national data ecosystem for thought leadership and mutual knowledge exchange to transform care delivery through next-gen insights.

Read More

Want to see what other hedge funds are holding HCAT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Health Catalyst, Inc. (NASDAQ:HCATGet Rating).

Institutional Ownership by Quarter for Health Catalyst (NASDAQ:HCAT)

Receive News & Ratings for Health Catalyst Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Health Catalyst and related companies with MarketBeat.com's FREE daily email newsletter.